ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
414 articles with ImmunoGen Inc.
-
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—...
-
AIT Bioscience’s Terri Pascarelli Recognized as a 2018 PharmaVOICE 100 honoree
8/3/2018
AIT Bioscience, LLC Chief Executive Officer, Terri Pascarelli has been named among the 2018 PharmaVOICE 100 honorees.
-
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
7/27/2018
Mirvetuximab Soravtansine Granted Fast Track Designation by FDA
-
ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer
6/18/2018
The designation is for the treatment of patients with medium to high folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy.
-
ImmunoGen Announces Closing of Public Offering of Common Stock
6/11/2018
ImmunoGen Inc., Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $11.00 per share.
-
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
6/7/2018
ImmunoGen, Inc. today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of $11.00 per share.
-
ImmunoGen Announces Proposed Public Offering of 12,000,000 Shares of Common Stock
6/5/2018
ImmunoGen, Inc. announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common stock in an underwritten public offering.
-
ImmunoGen Announces Webcast of Presentation at Jefferies 2018 Global Healthcare Conference
5/30/2018
ImmunoGen, Inc. announced that the Company will present at the upcoming Jefferies 2018 Global Healthcare Conference.
-
There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
-
ImmunoGen Reports Recent Progress and First Quarter 2018 Operating Results
5/4/2018
ImmunoGen, Inc. reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.
-
ImmunoGen Announces Webcast of Presentation at Deutsche Bank’s 43rd Annual Health Care Conference
5/2/2018
ImmunoGen, Inc. announced that the Company will present at the upcoming Deutsche Bank 43rd Annual Health Care Conference.
-
ImmunoGen Announces Successful Completion of Interim Analysis for FORWARD I Phase 3 Trial of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
4/26/2018
ImmunoGen, Inc. announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent therapy for the treatment of platinum-resistant ovarian cancer will continue as planned without modification.
-
ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
4/25/2018
ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer
-
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
-
ImmunoGen Announces Presentations at AACR Annual Meeting Highlighting Continued Innovation in ADCs
3/14/2018
ImmunoGen, Inc. announced that three posters highlighting the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 14-18, 2018 in Chicago.
-
3 Biotech Stocks That Soared Recently
2/19/2018
Three biotech stocks gained over 25 percent last week. -
ImmunoGen gave a pipeline progress report and 2017 operating results last week.
-
ImmunoGen Reports Pipeline Progress and 2017 Operating Results
2/9/2018
Revenues for the year ended December 31, 2017 were $115.4 million, compared to $48.6 million for the year ended December 31, 2016.
-
ImmunoGen Announces Conference Call to Discuss Its 2017 Operating Results
1/26/2018
ImmunoGen today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 9, 2018 to discuss its 2017 operating results.
-
ImmunoGen Appoints Stuart A. Arbuckle to Board of Directors
1/24/2018
Mr. Arbuckle is replacing Howard Pien, who is stepping down from ImmunoGen’s Board after eight years of service.